Oragenics Inc. (OGEN) News
Filter OGEN News Items
OGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest OGEN News From Around the Web
Below are the latest news stories about ORAGENICS INC that investors may wish to consider to help them evaluate OGEN as an investment opportunity.
Oragenics Issues Update to ShareholdersTAMPA, Fla., November 02, 2023--Oragenics, Inc. (NYSE American: OGEN): |
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of DirectorsTAMPA, Fla., October 18, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023. |
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug CandidateTAMPA, Fla. & LAS VEGAS, October 05, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Odyssey Health, Inc. (OTCQB: ODYY) ("Odyssey") announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as |
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy AssetsTAMPA, Fla., September 29, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics’ biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts. |
Oragenics, Inc. Announces Private PlacementTAMPA, Fla., August 07, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the "Private Placement Offering"), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the "Common Stock"), and (ii) 404,728 shares of S |
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDMTAMPA, Fla., June 05, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases, announces the award of a grant from CQDM, a Canadian bioresearch consortium, for the collaborative development of a variant-agnostic COVID-19 protein subunit vaccine candidate. The project, which aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1, is a collaboration with the National Research Council of |
Oragenics to Participate in the World Vaccine Congress WashingtonTAMPA, Fla., March 29, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C. |
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRETAMPA, Fla., March 14, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory testing of several compounds in Oragenics’ lantibiotics platform to combat multiple pathogens despite the resistance of those pathogens to standard-of-care antibiotics. Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infe |
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership TeamTAMPA, Fla., March 08, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023. Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies. |
Oragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing PactOragenics Inc (NYSE: OGEN) entered into an exclusive global license agreement with Inspirevax Inc for its novel intranasal mucosal adjuvant, BDX301, to develop NT-CoV2-1, Oragenics' lead intranasal COVID-19 vaccine candidate. Under the exclusive licensing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax's BDX301 intranasal mucosal adjuvant. The companies will form a Joint Development Committee (JDC) to oversee the development efforts collaboratively. Oragenics will m |